Spleen stiffness measurements using point shear wave elastography detects noncirrhotic portal hypertension in human immunodeficiency virus

Ayesha K. Ahmad, BSca, Sebastiana Atzori, MDa, Simon D. Taylor-Robinson, MB, BS, MD, FRCPa, James B. Maurice, MBChB, MRCPab, Graham S. Cooke, FRCP, DPhil (Oxon)c, Lucy Garvey, MB, ChB, FRCP, MDd,∗

Abstract
To assess the utility of spleen stiffness as a diagnostic tool in individuals with human immunodeficiency virus (HIV) and non-cirrhotic portal hypertension (NCPH).

The Philips EPIQ7, a new point shearwave elastography (pSWE) technique, was used to assess liver and spleen stiffness in 3 patient groups. Group 1: HIV and NCPH (n = 11); Group 2: HIV with past didanosine (ddl) exposure without known liver disease or NCPH (n = 5); Group 3: HIV without known liver disease or ddl exposure (n = 9).

Groups were matched for age, HIV chronicity, and antiretroviral treatment (including cumulative ddl exposure in Groups 1 and 2). Differences in liver and spleen stiffness (in kPa) between groups were analyzed using the Mann–Whitney U test.

Liver and spleen stiffness were both significantly higher in NCPH versus ddl-exposed (P = 0.019 and P = 0.006) and ddl-unexposed controls (P = 0.038 and P < 0.001). Spleen stiffness was more effective than liver stiffness at predicting NCPH, area under receiver operating characteristic (AUROC) 0.812 versus 0.948. Combining the 2 variables improved the diagnostic performance, AUROC 0.961. The optimal cut-off for predicting NCPH using splenic stiffness was 25.4kPa, with sensitivity 91%, specificity 93%, positive predictive value (PPV) 91%, negative predictive value (NPV) 93%, positive likelihood ratio 12.73, negative likelihood ratio 0.10. Spleen and liver stiffness scores were strongly correlated (P = 0.0004, 95% confidence interval [CI] 18, 59).

Elevated spleen stiffness is observed in HIV with NCPH and can be quantified easily using pSWE with high diagnostic accuracy. Novel strategies such as pSWE for longitudinal monitoring of patients with HIV and NCPH should be considered.

Abbreviations: AUROC = area under the receiver operating characteristic, ddl = didanosine, HIV = human immunodeficiency virus, kPa = kilopascal, LSM = liver stiffness measurement, NCPH = non-cirrhotic portal hypertension, NPV = negative predictive value, PPV = positive predictive value, pSWE = point shearwave elastography, SSM = spleen stiffness measurement, TE = transient elastography.

Keywords: human immunodeficiency virus, liver stiffness, non-cirrhotic portal hypertension, point shearwave elastography, spleen stiffness

1. Introduction
Portal hypertension in the absence of overt parenchymal chronic liver disease has been described in small cohorts of patients with human immunodeficiency virus (HIV) with complications including variceal bleeding and ascites.[1–3] Liver biopsy in these patients has commonly revealed features of nodular regenerative hyperplasia without liver cirrhosis, resulting in the development of non-cirrhotic portal hypertension (NCPH) with varices and splenomegaly. Liver histology and portal venous pressure measurements remain the gold standard for definitive diagnosis,[4] but are limited by their invasive and expensive nature, and therefore cannot be used for longitudinal monitoring and follow-up. These findings have primarily been attributed to didanosine (ddl) exposure, leading to the Federal Drug Agency (FDA) warning of NCPH and its use in clinical practice has now declined.[5] While this may avert further new diagnoses of HIV NCPH, the optimal management of established HIV NCPH patients is yet to be standardized.

Ultrasound elastography is now increasingly used as a non-invasive tool to identify hepatic fibrosis in a wide range of liver conditions with high positive and negative predictive values.[6,7] Transient elastography (TE), the most validated ultrasound
elastography technique, has recently been shown to have an association with the severity of portal hypertension in those with NCPH of various etiologies.\(^9\) However, given the wide range of liver stiffness measurements (LSM) that are described in NCPH, the utility of LSM using TE remains limited.\(^8\)

Point shearwave elastography (pSWE) is a novel form of elastography assessment, which has demonstrated similar sensitivity and specificity as TE in detecting fibrosis in individuals,\(^9,^{10}\) but it overcomes the main limitations of TE, namely its applicability in patients with large body habitus or ascites, simultaneous ultrasound morphological and fibrosis assessment and also an ability to assess more than one organ during the same examination without requiring recalibration.\(^9,^{10}\)

The spleen has now also become an organ of interest in the identification of portal hypertension and associated extra-hepatic complications such as esophageal varices.\(^11,^{12}\) Spleen stiffness measurements (SSM) have shown a superior association with the presence of portal hypertension compared with LSM in cirrhosis patients.\(^12,^{13}\) Thus far, neither splenic assessment or use of pSWE has been utilized in HIV cohorts as a potential indirect non-invasive marker of liver and portal system disease.

In this study, we aimed to assess SSM and LSM, measured by pSWE, in patients with and without NCPH, the latter stratified for prior ddI exposure.

2. Methods

2.1. Study design

In this prospective cross-sectional study, patients were recruited at the HIV Outpatient Department, Imperial College Healthcare NHS Trust. All patients were adults (over 18 years) and were receiving treatment for chronic HIV-1 antibody infection. It was a requirement of the study entry that patients had undetectable (<20 c/mL) plasma HIV RNA level for a minimum of 6 months. Patients were further stratified into 3 groups with the following inclusion criteria: Group 1: HIV + NCPH (defined as the presence of portal hypertension manifestations in the absence of cirrhosis diagnosed by liver biopsy); Group 2: HIV + past ddI exposure (without known NCPH or liver disease); Group 3: HIV and no ddI exposure or history of liver disease. Exclusion criteria included active infective or opportunistic illness, malignancy, pregnancy, cardiac failure, current hepatitis B/C infection, significant liver disease due to any cause and alcohol consumption in excess of current UK recommended limits. Groups were matched for age, HIV chronicity, and antiretroviral treatment (including cumulative ddI exposure in Groups 1 and 2). pSWE was performed using Philips EPIQ7 (ElastPQ, Philips Medical Systems, Seattle, WA). Patients were placed supine with arms abducted from the ultrasound probes and 10 stiffness measurements were taken from the right lobe of the liver and from the spleen. The median stiffness and IQR values were calculated for each region.

2.2. Ethics statement

This study was performed in accordance with the 1975 Declaration of Helsinki, with approvals from the Research Ethics Committee and the Joint Research and Compliance Office of Imperial College London and Imperial College Healthcare NHS Trust. Written informed consent was obtained from all patients (REC number: 15/LO/1749).

2.3. Statistics

Clinical and demographic data were collected. Associations between these parameters and liver and spleen stiffness were investigated using univariate linear regression analysis. Differences in liver and spleen stiffness (in kPa) between groups were analyzed using the Mann–Whiney U test. Diagnostic accuracy of spleen and liver stiffness in predicting the presence of NCPH was conducted using receiver operating characteristic (ROC) curves. Comparison of ROC curves using DeLong et al.\(^14\) methodology was used to compare differences between diagnostic tests.

3. Results

3.1. Study population

A total of 25 patients were recruited and included in the final analysis: 11 patients with HIV and NCPH (group 1), 5 with HIV

---

Table 1

Baseline characteristics of the patient population.

|                     | Group 1 HIV and NCPH (n = 11) | Group 2 HIV and ddI (n = 5) | Group 3 HIV and no ddI (n = 9) |
|---------------------|-------------------------------|----------------------------|-------------------------------|
| Age, (y, mean)      | 51                            | 50                         | 48                            |
| Male (n, %)         | 4 (36)                        | 5 (100)                    | 5 (56)                        |
| BMI (mean)          | 25.3                          | 23.9                       | 25.6                          |
| Mean time since HIV diagnosis, y | 20.3                        | 23.6                       | 15.4                          |
| HIV RNA <20 c/mL (n, %) | 11 (100)                    | 5 (100)                    | 5 (56)                        |
| Nadir CD4+ cell count, cells/μL | 106                         | 194                        | 201                           |
| Previous ddI (n, %) | 11 (100)                     | 5 (100)                    | 0 (0)                         |
| Total cumulative ddI exposure, mean, mo | 55                         | 53                         | 0                             |
| Gastropthy (n)      | 3                             | 0                          | 0                             |
| Varices (n)         | 10                            | 0                          | 0                             |
| Ascites (n)         | 0                             | 0                          | 0                             |
| Splenomegaly (n)    | 8                             | 0                          | 0                             |
| Bilirubin, μmol/L   | 25                            | 10                         | 10                            |
| ALT, IU/L           | 47                            | 35                         | 54                            |
| Platelets (×10^9)   | 89                            | 224                        | 271                           |
| Albumin, g/L        | 35                            | 39                         | 37                            |

ALT = alanine transaminase, BMI = body mass index, ddI = didanosine, HIV = human immunodeficiency virus, NCPH = non-cirrhotic portal hypertension.
and ddl exposure, but no NCPH (group 2), and 9 with HIV and no ddl exposure or NCPH (group 3). Clinical characteristics of patients are summarized in Table 1. The mean age was 49.7 years, 56% were men and 21 (84%) patients had an undetectable HIV RNA level. Current mean CD4+ count was 497 cells/\( \mu \)L and mean Nadir CD4+ count was 162 cells/\( \mu \)L. The mean time since HIV diagnosis was 19 years. ddl exposed patients had a cumulative mean of 34 months exposure.

### 3.2. Liver and spleen stiffness

Liver and spleen stiffness were both significantly higher in HIV patients with NCPH compared with ddl-exposed HIV patients and ddl-unexposed HIV controls (Fig. 1A and B). The median liver stiffness score in the NCPH cohort was 6.8 kPa (IQR: 2.53 kPa, range: 4–12 kPa), compared with 4.6 kPa (IQR: 1.27 kPa, range: 4–6 kPa, \( P = .019 \)) in ddl-exposed and 4.5 kPa (IQR: 1.03 kPa, range: 3–6 kPa, \( P = .038 \)) in ddl-unexposed individuals. Similarly, median spleen stiffness scores were higher in the NCPH cohort (76.3 kPa, IQR: 41.76 kPa, range: 18–197 kPa) than in the ddl-exposed (20.82 kPa, IQR: 5.52 kPa, range: 16.6–28.7 kPa, \( P = .006 \)) and ddl-unexposed groups (18.36 kPa, IQR: 6.63 kPa, range: 14.1–24.6 kPa, \( P < .001 \)). Spleen and liver stiffness scores were strongly correlated (\( r = .98 \)).

Overall, higher spleen stiffness was significantly associated with lower nadir CD4+ cell count (\( P < .0001 \), 95% CI -561, -344), lower current CD4+ cell count (\( P < .0001 \), 95% CI -167, -69), lower platelet count (\( P < .0001 \), 95% CI -184, -90), and higher serum bilirubin (\( P = .01 \), 95% CI 6.3, 49). However, no significant associations were found between serum ALT, albumin or cumulative ddl exposure (\( P > .05 \) for all measures).

Diagnostic performance through measures of area under receiver operating characteristic (AUROC) curves demonstrated that spleen stiffness showed non-statistically significant improvement compared with liver stiffness at predicting NCPH (AUROC 0.948 vs 0.812, \( P = .118 \)). When combining the 2 variables, diagnostic accuracy improved, however this was statistically insignificant (AUROC 0.961, \( P = .2949 \)). The optimal cut-off for predicting NCPH using splenic stiffness was 25.4 kPa, with sensitivity of 91%, specificity of 93%, positive predictive value of 91%, and negative predictive value of 93% (positive likelihood ratio 12.73, negative likelihood ratio 0.10).

### 4. Discussion

Currently, there is no consensus on the optimal long-term management strategy for the small numbers of people living with HIV and NCPH in the UK.\(^{15}\) We have demonstrated a potential non-invasive technique that can be used in the diagnosis and follow-up of such patients.

The sequelae of portal hypertension, including splenomegaly, portal venous congestion, and tissue hyperplasia may contribute to increased splenic stiffness, and therefore be associated with NCPH even in the absence of hepatic parenchymal damage.\(^{16}\) Non-invasive splenic stiffness assessment is presently being evaluated and shows promising use in portal hypertension caused by advanced chronic liver disease.\(^{17}\) Several techniques by which splenic stiffness can be assessed have been identified, but only TE has been previously used in NCPH.\(^{9,18}\) However, these studies have only assessed the use of liver stiffness and both present conflicting conclusions on its use as a potential diagnostic tool in NCPH of various etiologies.

To the best of our knowledge, this is the first paper to evaluate the use of spleen stiffness and pSWE to determine its utility in HIV patients with NCPH. We observed elevated spleen stiffness in our NCPH cohort, compared with ddl-exposed and unexposed controls. Moreover, our data suggest that NCPH can be quantified easily using pSWE with high diagnostic accuracy. Although further research is needed to validate our findings, the superior diagnostic value of pSWE compared with others, such as TE, is well established in cirrhotic portal hypertension.\(^{19–21}\) The mechanism by which some ddl-exposed individuals progress to NCPH, while others have no disruption to portal pressure, remains poorly understood.

Clearly our study is limited in its small and preliminary nature. While a larger sized study is desirable, the rare nature of this condition (HIV and NCPH) limits greatly the number of case subjects at our center. Nevertheless, we endeavored to match groups carefully according to clinical parameters (e.g., age, sex, HIV chronicity, and ddl exposure). We acknowledge that while...
we have demonstrated significant differences in spleen stiffness between groups, results should be interpreted with caution given the small size of the cohorts.

In summary, there are several clinical implications that arise from this study that are worthy of consideration. pSWE provides a rapid, non-invasive tool carrying minimal complications with higher applicability over other non-invasive techniques. It can also be implemented on regular ultrasound machines, which is likely to be both time-efficient and cost-effective for healthcare providers. As a result, novel strategies such as pSWE should be considered for longitudinal monitoring of HIV-positive individuals with NCPH. Future studies are needed to corroborate our findings, but we believe that spleen stiffness using ultrasonography is likely to have a significant positive impact in this small cohort of patients and further correlation of spleen stiffness and clinical outcomes should be evaluated.

Acknowledgments

Philips Medical Systems (Seattle, WA) provided the Philips EPIQ7TM system on loan to Imperial College London for this investigator-led study. The authors thank Mr James Jago and his team at Philips Medical Systems for their technical assistance with instrument set-up. They would like to thank all patients that participated in this work.

Author contributions

Conceptualization: Simon D. Taylor-Robinson, Graham S. Cooke, Lucy Garvey.

Data curation: Lucy Garvey.

Formal analysis: Sebastiana Maria Atzori, James B. Maurice, Lucy Garvey.

Investigation: Sebastiana Maria Atzori, Lucy Garvey.

Methodology: Simon D. Taylor-Robinson, Graham S. Cooke, Lucy Garvey.

Project administration: Lucy Garvey.

Resources: Simon D. Taylor-Robinson.

Software: Lucy Garvey.

Visualization: Simon D. Taylor-Robinson.

Writing – original draft: Ayesha Karim Ahmad, Lucy Garvey.

Writing – review & editing: Simon D. Taylor-Robinson, James B. Maurice, Graham S. Cooke, Lucy Garvey.

Ayesha Karim Ahmad orcid: 0000-0003-3763-1212.

References

[1] Schouten JNL, Garcia-Pagan JC, Valla DC, et al. Idiopathic noncirrhotic portal hypertension. Hepatology 2011;54:1071–81.

[2] Scourfield A, Waters L, Holmes P, et al. Non-cirrhotic portal hypertension in HIV-infected individuals. Int J STD AIDS 2011; 22:324–8.

[3] Mallev V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007;21:187–92.

[4] Ozgur Harmanci O, Bayraktar Y. Clinical characteristics of idiopathic portal hypertension. World J Gastroenterol 2007;13:1906–11.

[5] Research, Center for Drug Evaluation and. Postmarket Drug Safety Information for Patients and Providers - FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine); 2019.

[6] Oudry J, Chen J, Glaser KJ, et al. Cross-validation of magnetic resonance elastography and ultrasound-based transient elastography: a preliminary phantom study. J Magn Reson Imaging 2009;30:1145–50.

[7] Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343–50.

[8] Vuppalanchi R, Mathur K, Pyko M, et al. Liver stiffness measurements in patients with noncirrhotic portal hypertension—the devil is in the details. Hepatology 2018;68:2438–40.

[9] Bamber J, Cosgrove D, Dietrich CF, et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic principles and technology. Ultraschall Med 2013;34:169–84.

[10] Cosgrove D, Piscaglia F, Bamber J, et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 2: clinical applications. Ultraschall Med 2013;34:238–53.

[11] Fraquelli M, Guanta M, Pozzi R, et al. Feasibility and reproducibility of spleen transient elastography and its role in combination with liver spleen transient elastography for predicting the severity of chronic viral hepatitis. J Viral Hepat 2014;21:90–8.

[12] Sharma P, Kirnake V, Tyagi P, et al. Spleen stiffness in patients with cirrhosis in predicting esophageal varices. Am J Gastroenterol 2013; 108:1101–7.

[13] Collectcia A, Montrone L, Scialoi E, et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology 2012;143:646–54.

[14] DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.

[15] Vispo E, Morello J, Rodriguez-Novoa S, et al. Noncirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis 2011;24:12–8.

[16] Trovato FM, Atzori S, Musumeci G, et al. Liver and spleen transient elastography and acoustic radiation force impulse measurements. Performance and comparison of measurements in the same area concurrently assessed for liver fibrosis by biopsy. Adv Med Sci 2015; 60:300–6.

[17] Ravaiali F, Montagnani M, Lisotti A, et al. Noninvasive assessment of portal hypertension in advanced chronic liver disease: an update. Gastroenterol Res Pract 2018;2018:4202091–111.

[18] Sharma P, Agarwal R, Dhawan S, et al. Transient elastography (Fibroscan) in patients with non-cirrhotic portal fibrosis. J Clin Exp Hepatol 2017;7:230–4.

[19] Elkrief L, Ronot M, Morello J, et al. Performance and comparison of measurements in the same area concurrently assessed for liver fibrosis by biopsy. Adv Med Sci 2015; 60:300–6.

[20] Takuma Y, Morimoto Y, Takabatake H, et al. Measurement of spleen stiffness with acoustic radiation force impulse imaging predicts mortality and hepatic decompensation in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2017;15:1782,e4–90.e4.

[21] Attia D, Schonenmeier B, Rodt T, et al. Evaluation of liver and spleen stiffness with acoustic radiation force impulse quantification elastography for diagnosing clinically significant portal hypertension. Ultraschall Med 2015;36:603–10.